Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- FPMAJ Report on FY2008 NHI Price Revision
June 23, 2008
- Record-High 81 Applications Approved in FY2007
June 23, 2008
- REGULATORY NEWS IN BRIEF
June 23, 2008
- Nippon Shinyaku to Include RNA Drug Candidates in Its R&D Pipeline within 2 Years
June 23, 2008
- AnGes MG to Develop Gene Therapy for Mucopolysaccharidosis VI
June 23, 2008
- Guidance for MD Studies Completed
June 23, 2008
- Great Variability Seen in Clinical Data Packages Submitted for Applications in Japan: OPIR
June 23, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -2-
June 23, 2008
- R&D NEWS IN BRIEF -1-
June 23, 2008
- Otsuka, UCB Tie Up for Keppra and Cimzia in Japan
June 23, 2008
- R&D NEWS IN BRIEF -2-
June 23, 2008
- Asahi Kasei Pharma Licenses Treatment for Osteoarthritis
June 23, 2008
- MEDICAL DEVICE NEWS IN BRIEF
June 23, 2008
- Pfizer Beefs Up Promotion of Norvasc
June 23, 2008
- SELF-MEDICATION NEWS IN BRIEF
June 23, 2008
- Diovan Stays No. 1 for 3 Months in a Row: Rep Track Survey
June 23, 2008
- SEMINARS
June 23, 2008
- BUSINESS NEWS IN BRIEF
June 23, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -1-
June 23, 2008
- REGULATORY NEWS IN BRIEF
June 16, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…